Skip to Main Content
Skip Nav Destination

Issues

Journal Name Change

Vol. 1-12 (1944-1955) were published under the journal's founding title Schweizerische Zeitschrift für Tuberkulose, Vol. 13-18 (1956-1961) under its former title Schweizerische Zeitschrift für Tuberkulose und Pneumologie and Vol. 19-24 (1962-1967) as Medicina Thoracalis.

Respiration 2023, Vol. 102, No. 12

Clinical Investigations

Subject Area: Pharmacology , Pneumology
Respiration (2023) 102 (12): 969–977. https://doi.org/10.1159/000534276
Subject Area: Pharmacology , Pneumology
Respiration (2023) 102 (12): 978–985. https://doi.org/10.1159/000534920
Subject Area: Pharmacology , Pneumology
Respiration (2023) 102 (12): 986–990. https://doi.org/10.1159/000534922
Subject Area: Pharmacology , Pneumology
Respiration (2023) 102 (12): 991–994. https://doi.org/10.1159/000535127
Subject Area: Pharmacology , Pneumology
Respiration (2023) 102 (12): 995–1002. https://doi.org/10.1159/000535368

Interventional Pulmonology

Subject Area: Pharmacology , Pneumology
Respiration (2023) 102 (12): 1003–1006. https://doi.org/10.1159/000534673
Subject Area: Pharmacology , Pneumology
Respiration (2023) 102 (12): 1007–1015. https://doi.org/10.1159/000535234

Novel Insights from Clinical Practice

Subject Area: Pharmacology , Pneumology
Respiration (2023) 102 (12): 1016–1019. https://doi.org/10.1159/000534924
Established Facts

  • Tezepelumab and Dupilumab are approved antibodies for severe asthma.

  • Dupilumab is an IL4/13 receptor specific antibody that reduces Th2 cytokines, tezepelumab targets thymic stromal lymphopoietin, reduces exacerbations, and improves FEV1 in patients with severe asthma.

Acknowledgement to Reviewers

Subject Area: Pharmacology , Pneumology
Respiration (2023) 102 (12): 1020–1022. https://doi.org/10.1159/000534928

Contents

Subject Area: Pharmacology , Pneumology
Respiration (2023) 102 (12): I–VIII. https://doi.org/10.1159/000535616
Close Modal

or Create an Account

Close Modal
Close Modal